Axogen Stock Falls 9% on FDA Extension of PDUFA Goal Date
ByAInvest
Sunday, Sep 14, 2025 10:12 am ET1min read
AXGN--
The catalyst for this investigation was Axogen's announcement on August 25, 2025, that the U.S. Food and Drug Administration (FDA) had extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months, to December 5, 2025 [1]. This news led to a significant drop in Axogen's stock price, with shares falling by $1.47, or 9.04%, to close at $14.79 per share on the same day [1].
Investors who have held shares in Axogen are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss potential participation in the class action [1].
Raymond James Financial Inc., a major institutional investor, recently reduced its stake in Axogen by 8.0%, holding 254,129 shares valued at $4.70 million as of the end of the first quarter [2]. Despite this reduction, the current consensus rating for Axogen's stock remains "Buy," with a target price of $26.00 [2].
Analysts have expressed mixed opinions on Axogen's stock, with some upgrading the rating to "Buy" while others have set lower price objectives [2]. The company's stock has shown volatility, with a 12-month low of $9.22 and a 12-month high of $21.00 [2].
Axogen, Inc., along with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, and Axoguard HA+ Nerve Protector [2].
Pomerantz LLP is investigating claims on behalf of Axogen investors regarding potential securities fraud and unlawful business practices. The investigation concerns the company's announcement that the FDA extended the PDUFA goal date for its Biologics License Application by three months, causing a 9.04% drop in Axogen's stock price. Investors who have held shares in Axogen are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Pomerantz LLP, a prominent law firm specializing in securities litigation, has initiated an investigation into claims on behalf of investors of Axogen, Inc. (NASDAQ: AXGN). The investigation centers on whether Axogen and its officers or directors have engaged in securities fraud or other unlawful business practices [1].The catalyst for this investigation was Axogen's announcement on August 25, 2025, that the U.S. Food and Drug Administration (FDA) had extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months, to December 5, 2025 [1]. This news led to a significant drop in Axogen's stock price, with shares falling by $1.47, or 9.04%, to close at $14.79 per share on the same day [1].
Investors who have held shares in Axogen are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss potential participation in the class action [1].
Raymond James Financial Inc., a major institutional investor, recently reduced its stake in Axogen by 8.0%, holding 254,129 shares valued at $4.70 million as of the end of the first quarter [2]. Despite this reduction, the current consensus rating for Axogen's stock remains "Buy," with a target price of $26.00 [2].
Analysts have expressed mixed opinions on Axogen's stock, with some upgrading the rating to "Buy" while others have set lower price objectives [2]. The company's stock has shown volatility, with a 12-month low of $9.22 and a 12-month high of $21.00 [2].
Axogen, Inc., along with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, and Axoguard HA+ Nerve Protector [2].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
LEGAL
Privacy PolicyTerms of UseAIME Terms of UseBrokerage DisclaimerAI Risk DisclosuresEditorial PolicyCONTACT US
Email: support@ainvest.com, editorial@ainvest.com, corrections@ainvest.com, press@ainvest.com, legal@ainvest.com
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet